These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27350046)

  • 1. Limitations of the TheraMon
    Schramm C; Abaza A; Blumenstock G; Bechtold TE; Rickmann A; Bartz-Schmidt KU; Besch D; Januschowski K
    Acta Ophthalmol; 2016 Dec; 94(8):e753-e756. PubMed ID: 27350046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring wearing times of glasses and ocular patches using a thermosensor device from orthodontics.
    Januschowski K; Bechtold TE; Schott TC; Huelber-Januschowski MS; Blumenstock G; Bartz-Schmidt KU; Besch D; Schramm C
    Acta Ophthalmol; 2013 Dec; 91(8):e635-40. PubMed ID: 23759025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Use of a Microsensor in Therapy of Amblyopia].
    Januschowski K; Rickmann A; Emmerich C; Abaza A; Bechtold TE; Schott TC; Schramm C
    Klin Monbl Augenheilkd; 2019 Oct; 236(10):1170-1173. PubMed ID: 29117611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occlusion treatment for amblyopia: assessing the performance of the electronic occlusion dose monitor.
    Fronius M; Chopovska Y; Nolden J; Loudon SE; Lüchtenberg M; Zubcov A; Pepler L
    Strabismus; 2006 Jun; 14(2):65-70. PubMed ID: 16760110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of monitoring compliance with intermittent occlusion therapy glasses for amblyopia treatment.
    Wang J; Jin J; Malik A; Shoge R; Meiyeppen S; Pang Y; Yin K; Allen M; Scombordi B; Soni A; Neely DE; Januschowski K
    J AAPOS; 2019 Aug; 23(4):205.e1-205.e5. PubMed ID: 31271842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occlusion dose monitor available for electronic recording of compliance in patch wearing for amblyopia.
    Simonsz HJ
    Strabismus; 2012 Mar; 20(1):42. PubMed ID: 22390334
    [No Abstract]   [Full Text] [Related]  

  • 7. Electronic monitoring of treatment compliance in patching for amblyopia.
    Simonsz HJ; Polling JR; Voorn R; van Leeuwen J; Meester H; Romijn C; Dijkstra BG
    Strabismus; 1999 Jun; 7(2):113-23. PubMed ID: 10420216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wearing times of orthodontic devices as measured by the TheraMon® microsensor.
    Schott TC; Göz G
    J Orofac Orthop; 2011 Mar; 72(2):103-10. PubMed ID: 21503850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment monitoring and innovations in amblyopia treatment].
    Januschowski K; Emmerich C; Abaza A; Julich-Haertel H; Rickmann A
    Ophthalmologe; 2019 Dec; 116(12):1231-1234. PubMed ID: 31552468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How accurate are TheraMon® microsensors at measuring intraoral wear-time? Recorded vs. actual wear times in five volunteers.
    Brierley CA; Benson PE; Sandler J
    J Orthod; 2017 Dec; 44(4):241-248. PubMed ID: 28826346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal compliance for amblyopia therapy: occlusion with a translucent tape on the lens.
    Beneish RG; Polomeno RC; Flanders ME; Koenekoop RK
    Can J Ophthalmol; 2009 Oct; 44(5):523-8. PubMed ID: 19789586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Electronically recorded occlusion treatment in amblyopes older than 7 years: acuity gain after more than 4 months of treatment?].
    Kracht J; Bachert I; Diehl CM; Kämmerling S; Lüchtenberg M; Zubcov A; Simonsz H; Fronius M
    Klin Monbl Augenheilkd; 2010 Oct; 227(10):774-81. PubMed ID: 20963679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of wearing and occlusion times with smart shutter glasses-A proof of concept.
    Ihmig FR; Januschowski K; Koch T; Velten T; Rickmann A
    PLoS One; 2022; 17(6):e0270361. PubMed ID: 35749450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient compliance and orthodontic treatment efficacy of Planas functional appliances with TheraMon microsensors.
    Charavet C; Le Gall M; Albert A; Bruwier A; Leroy S
    Angle Orthod; 2019 Jan; 89(1):117-122. PubMed ID: 30080129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electronically measured compliance with occlusion therapy for amblyopia is related to visual acuity increase.
    Loudon SE; Polling JR; Simonsz HJ
    Graefes Arch Clin Exp Ophthalmol; 2003 Mar; 241(3):176-80. PubMed ID: 12644939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comfort of wear and material properties of eye patches for amblyopia treatment and the influence on compliance.
    Roefs AM; Tjiam AM; Looman CW; Simonsz-Toth B; Fronius M; Felius J; Simonsz HJ; Loudon SE
    Strabismus; 2012 Mar; 20(1):3-10. PubMed ID: 22390325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective Monitoring of Spectacle Wearing Times in Adult Subjects Using the Theramon
    Abaza A; Wahl G; Kortüm C; Januschowski K; Besch D; Schramm C
    Clin Ophthalmol; 2021; 15():1375-1389. PubMed ID: 33833496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Objectively monitored patching regimens for treatment of amblyopia: randomised trial.
    Stewart CE; Stephens DA; Fielder AR; Moseley MJ;
    BMJ; 2007 Oct; 335(7622):707. PubMed ID: 17855283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEDIG study on amblyopia; vision therapy by atropine penalization versus occlusion.
    Kowal L
    Binocul Vis Strabismus Q; 2002; 17(4):275. PubMed ID: 12470288
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized evaluation of spectacles plus alternate-day occlusion to treat amblyopia.
    Agervi P; Kugelberg U; Kugelberg M; Simonsson G; Fornander M; Zetterström C
    Ophthalmology; 2010 Feb; 117(2):381-7. PubMed ID: 20006908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.